Background: New indicators of potential human immunodeficiency virus (HIV) transmission are being actively explored. We aim to categorical testing of the viral load (VL) of persons living with HIV (PLWH) in order to explore new indicators to measure the intensity of the epidemic and the effectiveness of the response in the community.
Methods: A dynamic cohort study was conducted in Yining to monitor the VL of all persons living with HIV from 2017 to 2019. Different population VL (PVL) surrogate indicators were measured and the strength of the associations of different PVL surrogates with HIV incidence, antiretroviral therapy (ART) coverage, virus unsuppression, and viremia prevalence was assessed. PVL surrogate indicators were used to describe the current status of HIV transmission in different populations and communities.
Results: All PVL indicators decreased from 2017 to 2019 (P < 0.05). Arithmetic mean community viral load (CVL) (r = 1.000, P = 0.006) and geometric mean CVL (r = 1.000, P = 0.001) were positively associated with HIV incidence, ART coverage and viral unsuppression (P < 0.05). CVL was higher in the male, ≤ 25 years of age, primary school or below, other household registration, other medical insurance types, other source of sample, nonmarital and noncommercial heterosexual contact, and nonmarital and commercial heterosexual contact subgroups. Community-based cross-sectional analyses showed that CVL in community 10 was positively correlated with viral unsuppression rate and viremia prevalence but negatively correlated with ART coverage rate, suggesting that the community was a hotspot for HIV epidemics.
Conclusions: CVL can be used as an indicator for assessing HIV transmission and identifying high-risk populations and hotspot communities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725197 | PMC |
http://dx.doi.org/10.1186/s12889-025-21278-6 | DOI Listing |
Lancet Glob Health
January 2025
Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Institut National de la Santé et de la Recherche Médicale, Montpellier, France. Electronic address:
People who use drugs show a higher incidence and prevalence of tuberculosis than people who do not use drugs in areas where Mycobacterium tuberculosis is endemic. However, this population is largely neglected in national tuberculosis programmes. Strategies for active case finding, screening, and linkage to care designed for the general population are not adapted to the needs of people who use drugs, who are stigmatised and difficult to reach.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
January 2025
Department of Human Parasitology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China. Electronic address:
Objective: Transfusion-transmissible infections (TTIs) are severe threats to blood safety and public health. A retrospective study of blood donor records from 2015 to 2019 in Shiyan, China, was conducted.
Methods: TTI prevalence was analyzed using ELISA, RT-PCR, and demographic data.
HIV Res Clin Pract
December 2025
Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Background: HIV remains a major challenge in KwaZulu-Natal, South Africa, particularly for young women who face disproportionate risks and barriers to prevention and treatment. Most HIV cure trials, however, occur in high-income countries.
Objective: To examine the perspectives of young women diagnosed with acute HIV in a longitudinal study, focusing on their perceptions on ATI-inclusive HIV cure trials and the barriers and facilitators to participation.
Viruses
January 2025
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
Second-generation integrase strand transfer inhibitors (INSTIs) are strongly recommended for people living with HIV-1 (PLWH). The emergence of resistance to second-generation INSTIs has been infrequent and has not yet been a major issue in high-income countries. However, the delayed rollouts of these INSTIs in low- to middle-income countries during the COVID-19 pandemic combined with increased transmission of drug-resistant mutants worldwide are leading to an increase in INSTI resistance.
View Article and Find Full Text PDFViruses
January 2025
Centre for Virus Research, The Westmead Institute for Medical Research, Westmead 2145, Australia.
Anogenital inflammation is a critical risk factor for HIV acquisition. The primary preventative HIV intervention, pre-exposure prophylaxis (PrEP), is ineffective in blocking transmission in anogenital inflammation. Pre-existing sexually transmitted diseases (STIs) and anogenital microbiota dysbiosis are the leading causes of inflammation, where inflammation is extensive and often asymptomatic and undiagnosed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!